Core Viewpoint - The company announced a placement agreement to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13, 2026 [1] Group 1: Placement Details - The placement shares represent about 0.69% of the enlarged issued H shares and approximately 0.53% of the total issued shares after completion [1] - The expected total gross proceeds from the placement are approximately HKD 195 million, with net proceeds estimated at around HKD 190 million [1] - The net issue price is approximately HKD 90.54 per share [1] Group 2: Use of Proceeds - Approximately 60% of the net proceeds will be allocated to fund clinical trials for the core product Tinengotinib in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% will be allocated for working capital and general corporate purposes [1]
药捷安康-B(02617)拟折让约17.98%配售210万股 净筹约1.9亿港元